24.48 USD
+0.09 (+0.37%)
ACAD gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 533 industry peers in the Biotechnology industry. While ACAD has a great health rating, its profitability is only average at the moment. ACAD has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
ACAD had positive earnings in the past year.
In the past year ACAD had a positive cash flow from operations.
In the past 5 years ACAD always reported negative net income.
ACAD had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
ACAD has a better Return On Assets (19.63%) than 96.81% of its industry peers.
With an excellent Return On Equity value of 28.47%, ACAD belongs to the best of the industry, outperforming 97.37% of the companies in the same industry.
ACAD has a better Return On Invested Capital (7.66%) than 93.62% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 19.63% | ||
| ROE | 28.47% | ||
| ROIC | 7.66% |
ROA(3y)-13.43%
ROA(5y)-20.05%
ROE(3y)-13.54%
ROE(5y)-23.31%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ACAD's Profit Margin of 24.94% is amongst the best of the industry. ACAD outperforms 95.31% of its industry peers.
Looking at the Operating Margin, with a value of 9.02%, ACAD belongs to the top of the industry, outperforming 91.37% of the companies in the same industry.
The Gross Margin of ACAD (91.92%) is better than 92.50% of its industry peers.
In the last couple of years the Gross Margin of ACAD has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 9.02% | ||
| PM (TTM) | 24.94% | ||
| GM | 91.92% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.57%
GM growth 5Y2.57%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so ACAD is destroying value.
ACAD has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, ACAD has more shares outstanding
There is no outstanding debt for ACAD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
ACAD has an Altman-Z score of 5.45. This indicates that ACAD is financially healthy and has little risk of bankruptcy at the moment.
ACAD has a better Altman-Z score (5.45) than 75.05% of its industry peers.
ACAD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 5.45 |
ROIC/WACC0.88
WACC8.68%
2.3 Liquidity
ACAD has a Current Ratio of 3.02. This indicates that ACAD is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of ACAD (3.02) is worse than 63.04% of its industry peers.
A Quick Ratio of 2.94 indicates that ACAD has no problem at all paying its short term obligations.
The Quick ratio of ACAD (2.94) is worse than 61.91% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.02 | ||
| Quick Ratio | 2.94 |
3. Growth
3.1 Past
ACAD shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -14.10%.
Looking at the last year, ACAD shows a very strong growth in Revenue. The Revenue has grown by 121.75%.
EPS 1Y (TTM)-14.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%110%
Revenue 1Y (TTM)121.75%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%11.27%
3.2 Future
The Earnings Per Share is expected to grow by 39.38% on average over the next years. This is a very strong growth
ACAD is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.84% yearly.
EPS Next Y21.55%
EPS Next 2Y35.04%
EPS Next 3Y37.81%
EPS Next 5Y39.38%
Revenue Next Year10.06%
Revenue Next 2Y10.93%
Revenue Next 3Y10.69%
Revenue Next 5Y9.84%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 36.54, the valuation of ACAD can be described as expensive.
91.18% of the companies in the same industry are more expensive than ACAD, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 25.98, ACAD is valued a bit more expensive.
ACAD is valuated quite expensively with a Price/Forward Earnings ratio of 27.97.
91.37% of the companies in the same industry are more expensive than ACAD, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of ACAD to the average of the S&P500 Index (35.79), we can say ACAD is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 36.54 | ||
| Fwd PE | 27.97 |
4.2 Price Multiples
93.06% of the companies in the same industry are more expensive than ACAD, based on the Enterprise Value to EBITDA ratio.
ACAD's Price/Free Cash Flow ratio is rather cheap when compared to the industry. ACAD is cheaper than 94.93% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 18.97 | ||
| EV/EBITDA | 24.7 |
4.3 Compensation for Growth
ACAD's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
ACAD has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as ACAD's earnings are expected to grow with 37.81% in the coming years.
PEG (NY)1.7
PEG (5Y)N/A
EPS Next 2Y35.04%
EPS Next 3Y37.81%
5. Dividend
5.1 Amount
ACAD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:ACAD (11/26/2025, 9:46:09 AM)
24.48
+0.09 (+0.37%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners102.78%
Inst Owner Change1.37%
Ins Owners0.3%
Ins Owner Change0.15%
Market Cap4.13B
Revenue(TTM)1.05B
Net Income(TTM)261.17M
Analysts77.04
Price Target29.41 (20.14%)
Short Float %5.07%
Short Ratio4.05
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)96.34%
Min EPS beat(2)14.46%
Max EPS beat(2)178.22%
EPS beat(4)2
Avg EPS beat(4)20.1%
Min EPS beat(4)-109.07%
Max EPS beat(4)178.22%
EPS beat(8)5
Avg EPS beat(8)29%
EPS beat(12)7
Avg EPS beat(12)26.97%
EPS beat(16)10
Avg EPS beat(16)24.21%
Revenue beat(2)0
Avg Revenue beat(2)-1.06%
Min Revenue beat(2)-1.19%
Max Revenue beat(2)-0.93%
Revenue beat(4)1
Avg Revenue beat(4)-2.59%
Min Revenue beat(4)-8.33%
Max Revenue beat(4)0.08%
Revenue beat(8)3
Avg Revenue beat(8)-1.62%
Revenue beat(12)5
Avg Revenue beat(12)-0.37%
Revenue beat(16)6
Avg Revenue beat(16)-1.45%
PT rev (1m)-0.77%
PT rev (3m)-2.99%
EPS NQ rev (1m)15.12%
EPS NQ rev (3m)21.84%
EPS NY rev (1m)-1.41%
EPS NY rev (3m)1.31%
Revenue NQ rev (1m)2.27%
Revenue NQ rev (3m)2.24%
Revenue NY rev (1m)0.09%
Revenue NY rev (3m)0.09%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 36.54 | ||
| Fwd PE | 27.97 | ||
| P/S | 3.94 | ||
| P/FCF | 18.97 | ||
| P/OCF | 13 | ||
| P/B | 4.5 | ||
| P/tB | 5.13 | ||
| EV/EBITDA | 24.7 |
EPS(TTM)0.67
EY2.74%
EPS(NY)0.88
Fwd EY3.58%
FCF(TTM)1.29
FCFY5.27%
OCF(TTM)1.88
OCFY7.69%
SpS6.21
BVpS5.44
TBVpS4.78
PEG (NY)1.7
PEG (5Y)N/A
Graham Number9.05
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 19.63% | ||
| ROE | 28.47% | ||
| ROCE | 9.69% | ||
| ROIC | 7.66% | ||
| ROICexc | 58.65% | ||
| ROICexgc | 479.54% | ||
| OM | 9.02% | ||
| PM (TTM) | 24.94% | ||
| GM | 91.92% | ||
| FCFM | 20.79% |
ROA(3y)-13.43%
ROA(5y)-20.05%
ROE(3y)-13.54%
ROE(5y)-23.31%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.57%
GM growth 5Y2.57%
F-Score4
Asset Turnover0.79
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 711.57% | ||
| Cap/Sales | 9.55% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 292.92% | ||
| Profit Quality | 83.36% | ||
| Current Ratio | 3.02 | ||
| Quick Ratio | 2.94 | ||
| Altman-Z | 5.45 |
F-Score4
WACC8.68%
ROIC/WACC0.88
Cap/Depr(3y)241.55%
Cap/Depr(5y)203.25%
Cap/Sales(3y)567.7%
Cap/Sales(5y)341.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-14.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%110%
EPS Next Y21.55%
EPS Next 2Y35.04%
EPS Next 3Y37.81%
EPS Next 5Y39.38%
Revenue 1Y (TTM)121.75%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%11.27%
Revenue Next Year10.06%
Revenue Next 2Y10.93%
Revenue Next 3Y10.69%
Revenue Next 5Y9.84%
EBIT growth 1Y50.49%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-13.53%
EBIT Next 3Y32.73%
EBIT Next 5Y43.57%
FCF growth 1Y264.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y443.26%
OCF growth 3YN/A
OCF growth 5YN/A
ACADIA PHARMACEUTICALS INC / ACAD FAQ
What is the ChartMill fundamental rating of ACADIA PHARMACEUTICALS INC (ACAD) stock?
ChartMill assigns a fundamental rating of 5 / 10 to ACAD.
Can you provide the valuation status for ACADIA PHARMACEUTICALS INC?
ChartMill assigns a valuation rating of 6 / 10 to ACADIA PHARMACEUTICALS INC (ACAD). This can be considered as Fairly Valued.
Can you provide the profitability details for ACADIA PHARMACEUTICALS INC?
ACADIA PHARMACEUTICALS INC (ACAD) has a profitability rating of 6 / 10.
What is the earnings growth outlook for ACADIA PHARMACEUTICALS INC?
The Earnings per Share (EPS) of ACADIA PHARMACEUTICALS INC (ACAD) is expected to grow by 21.55% in the next year.